Dataset Information


Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

ABSTRACT: Large numbers of melanoma lesions develop resistance to targeted inhibition of mutant BRAF or fail to respond to checkpoint blockade. We explored whether modulation of intratumoral antigen-presenting cells (APCs) could increase responses to these therapies. Using mouse melanoma models, we found that CD103(+) dendritic cells (DCs) were the only APCs transporting intact antigens to the lymph nodes and priming tumor-specific CD8(+) T cells. CD103(+) DCs were required to promote anti-tumoral effects upon blockade of the checkpoint ligand PD-L1; however, PD-L1 inhibition only led to partial responses. Systemic administration of the growth factor FLT3L followed by intratumoral poly I:C injections expanded and activated CD103(+) DC progenitors in the tumor, enhancing responses to BRAF and PD-L1 blockade and protecting mice from tumor rechallenge. Thus, the paucity of activated CD103(+) DCs in tumors limits checkpoint-blockade efficacy and combined FLT3L and poly I:C therapy can enhance tumor responses to checkpoint and BRAF blockade.


PROVIDER: S-EPMC4980762 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7193033 | BioStudies
1000-01-01 | S-EPMC5785245 | BioStudies
2020-01-01 | S-EPMC7518441 | BioStudies
2020-01-01 | S-EPMC7394305 | BioStudies
2019-01-01 | S-EPMC6371497 | BioStudies
1000-01-01 | S-EPMC5084885 | BioStudies
2020-01-01 | S-EPMC7406262 | BioStudies
2019-01-01 | S-EPMC6935268 | BioStudies
2016-01-01 | S-EPMC5215252 | BioStudies
2019-01-01 | S-EPMC6865022 | BioStudies